Breatheasy Co.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Breatheasy Co. - overview
Established
2019
Location
Alameda, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2019 by founders Dalton Signor and Miist Therapeutics, doing business as Breatheasy Co. Miist Therapeutics offers inhalable medications designed to help individuals quit smoking by providing instant-acting therapies. In August 2024, Breatheasy Co. raised USD 6.
3 million in venture funding. Breatheasy's core products are its inhalation drug delivery systems. These systems are designed to allow patients to self-administer medication in a controlled dose through the respiratory system. The company has developed several types of inhalers, including dry powder inhalers (DPIs), metered dose inhalers (MDIs), and nebulizers, each suited for different patient needs and drug types.
Current Investors
Entrepreneur First, 1517 Fund, Refactor Capital
Primary Industry
Biotechnology
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.mymiist.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.